Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses

Under healthy conditions, soluble monomeric Aβ contributes to synaptic regulation, neuronal signaling, and neuroprotection through modulation of calcium homeostasis, metal ion binding, and antimicrobial defense.

“Under healthy conditions, soluble monomeric Aβ contributes to synaptic regulation, neuronal signaling, and neuroprotection through modulation of calcium homeostasis, metal ion binding, and antimicrobial defense [41–43].”

• cites [41] Hillen H (2019) The beta amyloid dysfunction (BAD) hypothesis for Alzheimer’s disease. Front Neurosci 13:1154. https://doi.org/10.3389/fnins.2019.01154 sourcePartly supported

  In “Aβ Monomer Homeostasis Is Essential for Synaptic Function” (page unavailable), the paper describes a physiological role for Aβ monomer in synaptic regulation, and Table 1 reports that it is neuroprotective. The passages do not support the claimed mechanisms of calcium-homeostasis modulation, metal-ion binding, or antimicrobial defense. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [42] Ricciarelli R, Fedele E (2017) The amyloid cascade hypothesis in Alzheimer’s disease: it’s time to change our mind. Curr Neuropharmacol 15(6):926–935. https://doi.org/10.2174/1570159X15666170116143743 sourcePartly supported

  The section “The physiological roles of APP and Aβ” (page unavailable) reports that physiological Aβ supports hippocampal synaptic plasticity, neurotransmitter release and neuronal viability. It also suggests an antimicrobial role, but attributes that role to soluble Aβ oligomers, not monomers. The copy does not establish monomer-specific benefits through calcium homeostasis or metal-ion binding; its discussion of calcium dysregulation concerns toxic effects. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [43] Puzzo D, Gulisano W, Arancio O, Palmeri A (2015) The keystone of Alzheimer pathogenesis might be sought in Aβ physiology. Neuroscience 307:26–36. https://doi.org/10.1016/j.neuroscience.2015.08.039 sourcePartly supported

  In “Aβ Between Pathology and Physiology” (page unavailable), the paper says low soluble Aβ has a physiological synaptic role, affects neurotransmitter release, and acts through mechanisms involving Ca2+ channels; it also reports that low Aβ concentrations can restore neuronal survival. It cautions that the species responsible for normal synaptic function is unknown, rather than establishing an exclusively monomeric role. The passages do not support metal-ion binding or antimicrobial defense as mechanisms of that role. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Repeated failure of amyloid-centric interventions to achieve meaningful clinical outcomes reveals the amyloid cascade hypothesis is inadequate as a unifying explanation for AD.

“This elegant yet reductionist model has guided therapeutic development for years; however, the repeated failure of amyloid-centric interventions to achieve meaningful clinical outcomes has revealed its inadequacy as a unifying explanation for the disease [8].”

• cites [8] Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, Zhang R, Wang H et al (2022) Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond. Transl Neurodegener 11(1):18. https://doi.org/10.1186/s40035-022-00292-3 sourcePartly supported

  The Abstract reports repeated failures of anti-Aβ clinical trials, and “Immunotherapies based on Aβ” says failed agents prompted reconsideration of Aβ as a therapeutic target (page numbers unavailable). But the paper does not conclude that these failures revealed the amyloid cascade hypothesis to be inadequate as a unifying explanation for AD; it also describes Aβ-targeted immunotherapy as potentially promising. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Soluble tau oligomers, rather than NFTs, are the primary neurotoxic species.

“While NFTs have long been viewed as toxic end-stage aggregates, increasing evidence suggests that soluble tau oligomers are the primary neurotoxic species.”

• cites [44] Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Reddy PH (2022) Phosphorylated tau in Alzheimer’s disease and other tauopathies. Int J Mol Sci 23(21):12841. https://doi.org/10.3390/ijms232112841 sourceCould not verify

  Section 4 describes tau oligomers as intermediates that form filaments and eventually NFTs, but does not compare their neurotoxicity with that of NFTs. The Introduction links NFT deposition to neuronal loss; it does not address whether soluble oligomers are the primary neurotoxic species. Searches for an oligomer-versus-NFT toxicity comparison found no passage that settles the claim. (LLM, conf=0.72)

  Experimental — accuracy not yet measured
• cites [45] Chen Y, Yu Y (2023) Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation. J Neuroinflammation 20:165. https://doi.org/10.1186/s12974-023-02853-3 sourceSupported

SHARPIN influences peripheral macrophage-mediated Aβ degradation, linking systemic inflammation to central amyloid burden.

“Similarly, proteins such as Shank-associated RH domain interactor (SHARPIN) influence peripheral macrophage-mediated Aβ degradation, linking systemic inflammation to central amyloid burden [37].”

• cites [37] Krishnan D, Menon RN, Mathuranath PS, Gopala S (2020) A novel role for SHARPIN in amyloid-β phagocytosis and inflammation by peripheral blood-derived macrophages in Alzheimer’s disease. Neurobiol Aging 93:131–141. https://doi.org/10.1016/j.neurobiolaging.2020.02.001 sourcePartly supported

  Section 3.1 reports that SHARPIN knockdown reduced Aβ uptake by THP-1-derived macrophages, and the Discussion links SHARPIN to macrophage inflammation and Aβ clearance. The study measured phagocytosis, not Aβ degradation or central amyloid burden; those more specific parts of the claim are not established by its results. Page numbers are unavailable in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Neuroinflammation exacerbates tau pathology, as activated microglia and astrocytes release cytokines that modulate kinase activity and impair clearance mechanisms.

“Neuroinflammation also exacerbates tau pathology, as activated microglia and astrocytes release cytokines that modulate kinase activity and impair clearance mechanisms [51].”

• cites [51] Davidson R, Krider RI, Borsellino P, Noorda K, Alhwayek G, Vida TA (2023) Untangling tau: molecular insights into neuroinflammation, pathophysiology, and emerging immunotherapies. Curr Issues Mol Biol 45(11):8816–8839. https://doi.org/10.3390/cimb45110553 sourcePartly supported

  Section 2 describes sustained cytokine release from activated glial cells, reduced clearance after prolonged microglial activation, tau aggregate propagation, and a possible contribution of astrocytes to tau hyperphosphorylation. Section 3.1 identifies kinases involved in tau phosphorylation, but the copy does not link cytokine release to altered kinase activity or establish that cytokines impair clearance. Page numbers were not provided. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Monoclonal antibodies targeting Aβ, including lecanemab and donanemab, demonstrate modest disease-modifying potential.

“More recently, monoclonal antibodies targeting amyloid-β (Aβ), including lecanemab and donanemab, have marked a milestone in the field by demonstrating modest disease-modifying potential [4, 5].”

• cites [4] Chundu UC, Thiriveedhi SR, Bhatti C, Mupparaju JS, Otinashvili N, Gelishvili E (2025) A systematic review of the efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer’s disease. Cureus 17(6):e85377. https://doi.org/10.7759/cureus.85377 sourceSupported
• cites [5] Nitrini R, Studart-Neto A (2025) Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer’s disease. Arq Neuropsiquiatr 83(5):1–5. https://doi.org/10.1055/s-0045-1808082 sourceSupported

NFTs, defining pathological hallmarks of AD, are composed of abnormally phosphorylated tau protein.

“The tau hypothesis is grounded in the discovery that neurofibrillary tangles (NFTs), one of the defining pathological hallmarks of AD, are composed of abnormally phosphorylated tau protein [44].”

• cites [44] Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Reddy PH (2022) Phosphorylated tau in Alzheimer’s disease and other tauopathies. Int J Mol Sci 23(21):12841. https://doi.org/10.3390/ijms232112841 sourceSupported

Phosphatases PP1, PP2A, and PP2B promote tau dephosphorylation.

“while phosphatases such as protein phosphatase (PP1, PP2A, and PP2B) promote tau dephosphorylation [45].”

• cites [45] Chen Y, Yu Y (2023) Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation. J Neuroinflammation 20:165. https://doi.org/10.1186/s12974-023-02853-3 sourcePartly supported

  In “Post-transcriptional modifications of tau” (page not provided), the review identifies PP2A as a phosphatase that regulates tau phosphorylation. It does not identify PP1 or PP2B there or state that all three promote tau dephosphorylation; searches for those specific phosphatases found no supporting passage. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Tau pathology promotes inflammatory signaling, creating a feed-forward loop.

“In turn, tau pathology promotes inflammatory signaling, creating a feed-forward loop.”

• cites [51] Davidson R, Krider RI, Borsellino P, Noorda K, Alhwayek G, Vida TA (2023) Untangling tau: molecular insights into neuroinflammation, pathophysiology, and emerging immunotherapies. Curr Issues Mol Biol 45(11):8816–8839. https://doi.org/10.3390/cimb45110553 sourceSupported

α-Secretase activity can be enhanced by PACAP, protein kinase C activators, and possibly environmental modulators.

“The regulation of α-secretase activity remains incompletely understood, although it can be enhanced by factors such as pituitary adenylate cyclase-activating peptide (PACAP), protein kinase C activators, and possibly environmental modulators [34].”

• cites [34] Hitschler L, Lang T (2022) The transmembrane domain of the amyloid precursor protein is required for antiamyloidogenic processing by α-secretase ADAM10. J Biol Chem 298(6):101911. https://doi.org/10.1016/j.jbc.2022.101911 sourcePartly supported

  The indexed passage labeled Abstract says ADAMs are regulated through protein kinase C and reports phorbol ester–stimulated α-cleavage; it also says the molecular details are not yet understood. The Discussion section on α-secretases as a treatment target discusses enhancing α-processing. Neither section supports PACAP or environmental modulators as enhancers of α-secretase activity. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Genetic discoveries have identified AD susceptibility loci beyond APOE, involved in lipid metabolism, endosomal trafficking, and immune regulation.

“Genetic discoveries have provided further depth, identifying susceptibility loci beyond apolipoprotein E (APOE), such as those involved in lipid metabolism, endosomal trafficking, and immune regulation [17].”

• cites [17] Belaidi AA, Bush AI, Ayton S (2025) Apolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities. Mol Neurodegener 20(1):47. https://doi.org/10.1186/s13024-025-00843-y sourcePartly supported

  The Neuroinflammation section (page unavailable) says genetic studies identified TREM2 variants associated with increased AD risk, supporting a susceptibility locus beyond APOE involved in immune regulation. The section on apoE receptors also discusses a genetic association involving LRP1B, but only for age at AD onset in a familial cohort. The copy does not establish the claimed set of susceptibility loci spanning lipid metabolism and endosomal trafficking. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

AD is a multi-hit disorder in which cumulative insults, rather than a single initiating event, drive disease onset and progression.

“The convergence of these mechanisms supports the concept of AD as a multi-hit disorder in which cumulative insults, rather than a single initiating event, drive disease onset and progression [23].”

• cites [23] Bellenguez C, Küçükali F, Jansen IE et al (2022) New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet 54(4):412–436. https://doi.org/10.1038/s41588-022-01024-z sourcePartly supported

  The Pathway analyses and Discussion sections identify multiple AD-associated pathways and describe complex crosstalk between brain cell types. They do not establish the claimed multi-hit sequence in which cumulative insults, rather than a single initiating event, drive disease onset and progression. Page numbers are not available in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Autophagy-lysosomal dysfunction is a critical mechanism impairing clearance of pathological proteins in AD.

“Autophagy–lysosomal dysfunction has emerged as a critical mechanism impairing the clearance of pathological proteins [16].”

• cites [16] Orr ME, Oddo S (2013) Autophagic/lysosomal dysfunction in Alzheimer’s disease. Alzheimers Res Ther 5(5):53. https://doi.org/10.1186/alzrt217 sourceSupported

FDG-PET imaging has demonstrated markedly reduced glucose uptake in temporoparietal association cortices, posterior cingulate, and hippocampal regions of patients with MCI and early AD, often preceding overt clinical symptoms.

“FDG-PET imaging has demonstrated markedly reduced glucose uptake in temporoparietal association cortices, the posterior cingulate, and hippocampal regions of patients with mild cognitive impairment (MCI) and early AD, often preceding overt clinical symptoms [67].”

• cites [67] González A, Calfío C, Churruca M et al (2022) Glucose metabolism and AD: evidence for a potential diabetes type 3. Alz Res Ther 14:56. https://doi.org/10.1186/s13195-022-00996-8 sourcePartly supported

  The Insulin resistance section (page unavailable) associates impaired glucose metabolism with AD and describes FDG-PET as a proposed biomarker of brain carbohydrate metabolism. It does not report FDG-PET findings for the named brain regions in patients with MCI or early AD, or establish that reduced uptake precedes clinical symptoms. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Neuronal glucose utilization is largely insulin-independent, relying on facilitative glucose transporters, particularly GLUT1 in endothelial cells and astrocytes and GLUT3 in neurons.

“While peripheral tissues depend heavily on insulin for glucose uptake, neuronal glucose utilization is largely insulin-independent, relying instead on facilitative glucose transporters (GLUTs), particularly GLUT1 in endothelial cells and astrocytes and GLUT3 in neurons [71].”

• cites [71] Panahi M, Rodriguez PR, Fereshtehnejad SM, Arafa D, Bogdanovic N, Winblad B, Cedazo-Minguez A, Rinne J et al (2020) Insulin-independent and dependent glucose transporters in brain mural cells in CADASIL. Front Genet 11:1022. https://doi.org/10.3389/fgene.2020.01022 sourcePartly supported

  The Introduction says glucose transport is mainly facilitated by GLUTs, and the Discussion identifies GLUT1 as the major transporter in endothelial cells. The paper’s insulin-independence findings concern vascular smooth muscle cells, not neurons; the passages do not establish that neuronal glucose use is largely insulin-independent or identify GLUT1 in astrocytes and GLUT3 in neurons (pages not supplied). (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Cerebral hypometabolism, particularly reduced glucose metabolism, is a consistent and defining feature of AD.

“Cerebral hypometabolism or a reduction in the metabolic activity of brain cells, particularly glucose metabolism, is a consistent and defining feature of AD [66].”

• cites [66] Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L (2023) Hypometabolism, Alzheimer’s disease, and possible therapeutic targets: an overview. Cells 12(16):2019. https://doi.org/10.3390/cells12162019 sourcePartly supported

  Section 2, “Hypometabolism in AD” (page not provided), calls brain hypometabolism a major feature of AD and describes repeated findings of impaired glucose uptake. But Section 6, “Discussion and Conclusions” (page not provided), says hypometabolism is not specific to AD or a primary diagnostic criterion, so “defining” overstates the source if it implies a distinguishing feature. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Insulin resistance, common in type 2 diabetes, may influence AD risk more through systemic inflammation and vascular dysfunction than through direct effects on neuronal glucose uptake.

“Insulin resistance, common in type 2 diabetes, may therefore influence AD risk more through systemic inflammation and vascular dysfunction than through direct effects on neuronal glucose uptake [78].”

• cites [78] Ponce-Lopez T (2025) Peripheral inflammation and insulin resistance: their impact on blood-brain barrier integrity and glia activation in Alzheimer’s disease. Int J Mol Sci 26(9):4209. https://doi.org/10.3390/ijms26094209 sourceSupported

Mitochondrial oxidative stress activates GSK3β and CDK5, promoting tau hyperphosphorylation.

“Mechanistically, abnormal localization of APP to mitochondria-associated membranes alters γ-secretase function and enhances Aβ generation [61], while mitochondrial oxidative stress activates kinases such as GSK3β and CDK5, promoting tau hyperphosphorylation [62].”

• cites [62] Wu X, Yang Z, Zou J, Gao H, Shao Z, Li C, Lei P (2025) Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery. Signal Transduct Target Ther 10(1):146. https://doi.org/10.1038/s41392-025-02179-x sourcePartly supported

  In the AD section (GSK3β and CDK5 subsections; page unavailable), the paper says these kinases promote tau phosphorylation, including hyperphosphorylation. Figure 5 also describes oxidative stress as a condition that can lead to CDK5 overactivation. The cited passages do not establish the more specific claim that mitochondrial oxidative stress activates both CDK5 and GSK3β; the AD section instead describes GSK3β activity and CDK5 dysfunction as contributing to oxidative stress or mitochondrial dysfunction. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Risk variants in glial cell surface genes TREM2, CD33, and ABCA7, enriched in microglia, significantly increase susceptibility to AD.

“Genetic studies underscore the centrality of glial dysfunction, with risk variants in glial cell surface genes, such as triggering receptor expressed on myeloid cells 2 (TREM2), siglec-3 (CD33), and ATP-binding cassette subfamily A member 7 (ABCA7), which are enriched in microglia, significantly increasing susceptibility to AD [89].”

• cites [89] Sun Z, Zhang X, So K-F, Jiang W, Chiu K (2024) Targeting microglia in Alzheimer’s disease: pathogenesis and potential therapeutic strategies. Biomolecules 14(7):833. https://doi.org/10.3390/biom14070833 sourcePartly supported

  Section 3.1 (page unavailable) identifies TREM2 and ABCA7 among AD-susceptibility genes preferentially expressed in microglia, and separately calls CD33 an AD-susceptibility gene widely observed on microglia. It identifies TREM2 as a cell-surface receptor and CD33 as a transmembrane protein, but does not establish that ABCA7 is a cell-surface gene or that variants in each of the three significantly increase susceptibility. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Exosomes act as vehicles for intercellular transfer of Aβ, tau, and inflammatory mediators between neurons, astrocytes, and microglia, facilitating spread of pathology.

“Moreover, crosstalk between inflammasomes and exosomes introduces an additional regulatory dimension, whereby exosomes act as vehicles for the intercellular transfer of Aβ, tau, and inflammatory mediators between neurons, astrocytes, and microglia, thereby facilitating the spread of pathology (Fig. 6).”

• cites [91] Singh J, Habean ML, Panicker N (2023) Inflammasome assembly in neurodegenerative diseases. Trends Neurosci 46(10):814–831. https://doi.org/10.1016/j.tins.2023.07.009 sourceCould not verify

  The passages on tau pathology and microglia–astrocyte crosstalk (indexed as Abstract; page unavailable) describe inflammasome effects, including transfer of fragmented mitochondria, but not exosome-mediated transfer of Aβ, tau, or inflammatory mediators. Searches for “exosomes” and “extracellular vesicles” found no passage addressing the claimed mechanism. (LLM, conf=0.75)

  Experimental — accuracy not yet measured

Aβ deposition, tau hyperphosphorylation, and neuroinflammation exacerbate metabolic impairment by further disrupting glucose transport and mitochondrial function.

“On the other hand, Aβ deposition, tau hyperphosphorylation, and neuroinflammation exacerbate metabolic impairment by further disrupting glucose transport and mitochondrial function [75].”

• cites [75] Song T, Song X, Zhu C, Patrick R, Skurla M, Santangelo I, Green M, Harper D et al (2021) Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer’s disease: a meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res Rev 72:101503. https://doi.org/10.1016/j.arr.2021.101503 sourcePartly supported

  The Discussion (page unavailable) links Aβ to microglial activation and describes neuroinflammation, mitochondrial dysfunction, and metabolic alterations as intertwined in Alzheimer’s disease. It does not say that Aβ deposition, tau hyperphosphorylation, and neuroinflammation worsen metabolism by disrupting glucose transport and mitochondrial function; it also notes that mitochondrial dysfunction may precede amyloid deposition. Searches for glucose transport and tau hyperphosphorylation did not establish those specific mechanisms. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Proinflammatory cytokines enhance tau phosphorylation through kinase activation pathways involving CDK5, GSK-3, and MAPKs, thereby accelerating neurofibrillary tangle formation.

“Proinflammatory cytokines enhance tau phosphorylation through kinase activation pathways involving CDK5, GSK-3, and MAPKs, thereby accelerating neurofibrillary tangle formation [92] (Fig. 6).”

• cites [92] Novoa C, Salazar P, Cisternas P et al (2022) Inflammation context in Alzheimer’s disease, a relationship intricate to define. Biol Res 55:39. https://doi.org/10.1186/s40659-022-00404-3 sourcePartly supported

  The “Neuroinflammation related to tau” section (page unavailable) says neuroinflammation could play a role in tau hyperphosphorylation and neurofibrillary tangle formation. It does not establish the claimed CDK5/GSK-3/MAPK pathway or accelerated tangle formation; its p38 MAPK passage instead describes extracellular tau activating a pathway in microglia that increases cytokine expression. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

A reduction in presynaptic input initiates maladaptive responses that ultimately promote the formation of NFTs.

“Specifically, a reduction in presynaptic input initiates maladaptive responses that ultimately promote the formation of NFTs.”

• cites [80] Toricelli M, Pereira AAR, Souza Abrao G, Malerba HN, Maia J, Buck HS, Viel TA (2021) Mechanisms of neuroplasticity and brain degeneration: strategies for protection during the aging process. Neural Regen Res 16(1):58–67. https://doi.org/10.4103/1673-5374.286952 sourceCould not verify

  The Neuroplasticity and Cell Survival section discusses presynaptic signaling, while the Cell senescence, neurodegeneration and neuroprotection section links tau phosphorylation to cellular toxicity. Neither passage says that reduced presynaptic input initiates responses that lead to neurofibrillary tangles. Searches for that causal sequence and for neurofibrillary tangles found no supporting passage in our copy. (LLM, conf=0.72)

  Experimental — accuracy not yet measured
• cites [81] Kawabata S (2022) Excessive/aberrant and maladaptive synaptic plasticity: a hypothesis for the pathogenesis of Alzheimer’s disease. Front Aging Neurosci 14:913693. https://doi.org/10.3389/fnagi.2022.913693 sourcePartly supported

  The Conclusion proposes that NFTs may be byproducts of excessive or aberrant synaptic plasticity. The Mechanism of Network Abnormalities describes reduced synapses at a site of entorhinal input alongside possible compensatory reweighting, but does not establish reduced presynaptic input as the initiator of a pathway to NFTs. The citing sentence also states as fact a connection the paper presents as a hypothesis. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Cybrid models demonstrate that mitochondrial defects alone can recapitulate key AD phenotypes, including decreased complex IV activity, increased ROS generation, synaptic dysfunction, and enhanced Aβ and phosphorylated tau accumulation.

“Evidence from cytoplasmic hybrid (cybrid) models, where mitochondria from AD patients are transferred into mtDNA-depleted cells, demonstrates that mitochondrial defects alone can recapitulate key AD phenotypes, including decreased complex IV activity, increased ROS generation, synaptic dysfunction, and enhanced Aβ and phosphorylated tau accumulation [59, 60].”

• cites [59] Swerdlow RH, Koppel S, Weidling I, Hayley C, Ji Y, Wilkins HM (2017) Mitochondria, cybrids, aging, and Alzheimer’s disease. Prog Mol Biol Transl Sci 146:259–302. https://doi.org/10.1016/bs.pmbts.2016.12.017 sourcePartly supported

  The AD Cybrid Experiments section reports reduced complex IV (COX) activity, increased oxidative-stress markers, and increased Aβ levels in AD cybrids. It does not report synaptic dysfunction or phosphorylated tau accumulation in those cybrids, and oxidative-stress markers do not directly establish increased ROS generation. The Implications and Limitations section says mitochondrial function can contribute to these changes, rather than demonstrating that mitochondrial defects alone cause them. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [60] Miller DM, Archer SL, Dunham-Snary KJ (2025) Preclinical models of mitochondrial dysfunction: mtDNA and nuclear-encoded regulators in diverse pathologies. Front Aging 6:1585508. https://doi.org/10.3389/fragi.2025.1585508 sourcePartly supported

  Section 1.3.1 describes cybrids as mtDNA-depleted cells receiving donor mitochondria and says they can isolate the influence of introduced mtDNA. Sections 1.3 and 1.4 report respiratory-chain defects and oxidative stress in cybrid models of other diseases, but our copy does not report AD-patient cybrids or the claimed synaptic dysfunction, Aβ accumulation, and phosphorylated tau accumulation. The complex IV reduction it describes is in MELAS cybrids, not AD cybrids. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Brain regions critically involved in cognition, such as the hippocampus, amygdala, and prefrontal cortex, are especially vulnerable in AD.

“Brain regions critically involved in cognition, such as the hippocampus, amygdala, and prefrontal cortex, are especially vulnerable [84].”

• cites [84] Marzola P, Melzer T, Pavesi E, Gil-Mohapel J, Brocardo PS (2023) Exploring the role of neuroplasticity in development, aging, and neurodegeneration. Brain Sci 13(12):1610. https://doi.org/10.3390/brainsci13121610 sourcePartly supported

  Section 4.3 says the hippocampus is particularly affected by aging, and Section 4.1 says aging particularly affects the hippocampus and cerebral cortex while increasing the risk of AD. Neither passage establishes that the hippocampus, amygdala, and prefrontal cortex are all especially vulnerable in AD; the discussion of the amygdala and prefrontal cortex in Section 3.3 concerns adolescence. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Iron overload can trigger ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation and mitochondrial shrinkage.

“Moreover, iron overload can trigger ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation and mitochondrial shrinkage [108].”

• cites [108] Puentes-Díaz N, Chaparro D, Morales-Morales D, Flores-Gaspar A, Alí-Torres J (2023) Role of metal cations of copper, iron, and aluminum and multifunctional ligands in Alzheimer’s disease: experimental and computational insights. ACS Omega 8(5):4508–4526. https://doi.org/10.1021/acsomega.2c06939 sourcePartly supported

  The “Oxidative Stress in AD” section (page unavailable) links pathological iron levels to mitochondrial dysfunction and says iron-generated reactive oxygen species can damage lipids. It does not identify ferroptosis as the resulting cell-death mechanism or describe mitochondrial shrinkage; searches for those terms found no supporting passage. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Selective vulnerability of basal forebrain cholinergic neurons is often attributed to deficiency of NGF, which normally sustains them.

“This selective vulnerability is often attributed to a deficiency of nerve growth factor (NGF), which normally sustains basal forebrain cholinergic neurons.”

• cites [97] Geula C, Dunlop SR, Ayala I, Kawles AS, Flanagan ME, Gefen T, Mesulam MM (2021) Basal forebrain cholinergic system in the dementias: vulnerability, resilience, and resistance. J Neurochem 158(6):1394–1411. https://doi.org/10.1111/jnc.15471 sourcePartly supported

  Section 5 says Ch1–Ch4 neurons depend on NGF for survival and considers NGF deficiency a conceivable cause of selective vulnerability. It does not say this explanation is often invoked; it also reports no loss or an increase in cortical and hippocampal NGF in AD, consistent with defective transport instead. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

ROS-induced activation of microglia and astrocytes fuels a chronic neuroinflammatory response.

“Furthermore, ROS-induced activation of microglia and astrocytes fuels a chronic neuroinflammatory response, while transition metals (iron, copper, zinc) and Aβ–metal complexes act as potent redox catalysts, amplifying free radical production [103].”

• cites [103] Roy RG, Mandal PK, Maroon JC (2023) Oxidative stress occurs prior to amyloid Aβ plaque formation and tau phosphorylation in Alzheimer’s disease: role of glutathione and metal ions. ACS Chem Neurosci 14(17):2944–2954. https://doi.org/10.1021/acschemneuro.3c00486 sourcePartly supported

  The Introduction’s “Role of Reactive Oxygen Species in AD” section links microglial activation to a neuroinflammatory enzyme that produces ROS. It does not say that ROS activates microglia or astrocytes, or that their activation sustains a chronic neuroinflammatory response; the causal direction it describes is different. Page numbers were not available in our copy. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

Under physiological conditions, trace metals iron, copper, and zinc are tightly regulated to support essential neuronal processes including enzymatic activity, neurotransmission, antioxidant defense, and synaptic plasticity.

“Under physiological conditions, trace metals such as iron (Fe), copper (Cu), and zinc (Zn) are tightly regulated to support essential neuronal processes, including enzymatic activity, neurotransmission, antioxidant defense, and synaptic plasticity [106].”

• cites [106] Cristóvão JS, Santos R, Gomes CM (2016) Metals and neuronal metal binding proteins implicated in Alzheimer’s disease. Oxid Med Cell Longev 2016:9812178. https://doi.org/10.1155/2016/9812178 sourcePartly supported

  Section 2 says iron, copper, and zinc play essential roles in the brain and that their homeostasis is important for neuronal function. Section 2.6 describes zinc loading into presynaptic vesicles, but the copy does not establish the full list of functions attributed to these metals—particularly antioxidant defense and synaptic plasticity under physiological conditions. No page numbers are available in the indexed copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

In AD, overstimulation of NMDA receptors displaces Mg2+, resulting in uncontrolled influx of Ca2+ and Na+ ions.

“In AD, however, this finely tuned system becomes dysregulated. Overstimulation of NMDA receptors displaces Mg2+, resulting in uncontrolled influx of Ca2+ and sodium (Na+) ions.”

• cites [117] Hou H, Wang L, Fu T, Papasergi M, Yule DI, Xia H (2020) Magnesium acts as a second messenger in the regulation of NMDA receptor-mediated CREB signaling in neurons. Mol Neurobiol 57(6):2539–2550. https://doi.org/10.1007/s12035-020-01871-z sourcePartly supported

  The Introduction and Discussion (page numbers unavailable) state that Mg2+ blocks NMDA receptors and that membrane depolarization can relieve the block. The Results report Ca2+ responses to NMDA in cultured neurons. The paper does not establish that, in Alzheimer’s disease, receptor overstimulation displaces Mg2+ or causes uncontrolled Ca2+ and Na+ influx. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Ca2+ overload exacerbates mitochondrial dysfunction, creating a vicious cycle of impaired bioenergetics and oxidative stress.

“Ca2+ overload exacerbates mitochondrial dysfunction, creating a vicious cycle of impaired bioenergetics and oxidative stress [117].”

• cites [117] Hou H, Wang L, Fu T, Papasergi M, Yule DI, Xia H (2020) Magnesium acts as a second messenger in the regulation of NMDA receptor-mediated CREB signaling in neurons. Mol Neurobiol 57(6):2539–2550. https://doi.org/10.1007/s12035-020-01871-z sourceCould not verify

  The Introduction discusses glutamate toxicity and CREB signaling, while the Discussion addresses magnesium- and calcium-dependent CREB activation. Our copy does not address whether Ca2+ overload worsens mitochondrial dysfunction or creates a cycle of impaired bioenergetics and oxidative stress (searched for mitochondrial dysfunction, oxidative stress, calcium overload, and reactive oxygen species). No page numbers were available in the indexed passages. (LLM, conf=0.73)

  Experimental — accuracy not yet measured

Loss of trophic support combined with metabolic and proteostatic stressors renders basal forebrain cholinergic neurons especially susceptible to degeneration in AD.

“Loss of trophic support, combined with metabolic and proteostatic stressors, renders these neurons especially susceptible to degeneration in AD [97].”

• cites [97] Geula C, Dunlop SR, Ayala I, Kawles AS, Flanagan ME, Gefen T, Mesulam MM (2021) Basal forebrain cholinergic system in the dementias: vulnerability, resilience, and resistance. J Neurochem 158(6):1394–1411. https://doi.org/10.1111/jnc.15471 sourcePartly supported

  Section 5, “Selective Vulnerability of Basal Forebrain Cholinergic System” (page unavailable), says disrupted retrograde NGF transport is likely to contribute to cholinergic neuron loss in AD. It also links neurofibrillary tangles to degeneration, but the cited passages do not establish metabolic stress or characterize the pathology as proteostatic stress acting in combination with lost trophic support. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Dysregulation of metal ion homeostasis is a critical factor in AD pathogenesis.

“The dysregulation of metal ion homeostasis has emerged as a critical factor in AD pathogenesis.”

• cites [106] Cristóvão JS, Santos R, Gomes CM (2016) Metals and neuronal metal binding proteins implicated in Alzheimer’s disease. Oxid Med Cell Longev 2016:9812178. https://doi.org/10.1155/2016/9812178 sourceSupported

AChEIs donepezil, rivastigmine, and galantamine enhance synaptic ACh availability by delaying enzymatic degradation.

“Acetylcholinesterase inhibitors (AChEIs), such as donepezil, rivastigmine, and galantamine, which were approved more than two decades ago, enhance synaptic acetylcholine (ACh) availability by delaying its enzymatic degradation.”

• cites [99] Crittenden JR, Zhai S, Sauvage M, Kitsukawa T, Burguière E, Thomsen M, Zhang H, Costa C et al (2021) Caldag-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors. Neurobiol Dis 158:105473. https://doi.org/10.1016/j.nbd.2021.105473 sourceCould not verify

  The Discussion (page unavailable) addresses striatal muscarinic signaling and CDGI, not acetylcholinesterase inhibitors. Searches for donepezil, the three named drugs, and acetylcholine degradation found no passage in our copy supporting their mechanism or approval history. (LLM, conf=0.74)

  Experimental — accuracy not yet measured

Microglia and astrocytes contribute by releasing glutamate under inflammatory conditions, amplifying excitotoxic signaling.

“Microglia and astrocytes also contribute by releasing glutamate under inflammatory conditions, amplifying excitotoxic signaling [118].”

• cites [118] Cekanaviciute E, Buckwalter MS (2016) Astrocytes: integrative regulators of neuroinflammation in stroke and other neurological diseases. Neurotherapeutics 13(4):685–701. https://doi.org/10.1007/s13311-016-0477-8 sourcePartly supported

  The section on reactive astrocytes reports that, in slice cultures, microglia release TNF-α, which prompts astrocytes to release glutamate and amplify excitotoxicity (page not available in our copy). It supports astrocytic glutamate release and microglial involvement, but not the claim that microglia also release glutamate in this mechanism. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Clinical trials of NSAIDs in MCI and established AD have yielded largely negative results.

“While epidemiological studies suggested that chronic non-steroidal anti-inflammatory drug (NSAID) use might lower AD risk, clinical trials in MCI and established AD have yielded largely negative results.”

• cites [94] Rivers-Auty J, Mather AE, Peters R, Lawrence CB, Brough D (2020) Anti-inflammatories in Alzheimer’s disease-potential therapy or spurious correlate? Brain Commun 2(2):fcaa109. https://doi.org/10.1093/braincomms/fcaa109 sourcePartly supported

  The Introduction (page unavailable) reports that several NSAID trials found no significant effect on Alzheimer’s disease progression, supporting the claim about established AD. The paper also studies people with MCI, but that analysis uses a longitudinal dataset rather than clinical trials; the cited passages do not establish negative trial results in MCI. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

MPACs are designed to modulate metal-Aβ interactions without causing systemic depletion.

“More recent approaches focus on metal–protein attenuating compounds (MPACs) designed to modulate metal–Aβ interactions without causing systemic depletion [113].”

• cites [113] Vilella A, Daini E, De Benedictis CA, Grabrucker AM (2020) Targeting metal homeostasis as a therapeutic strategy for Alzheimer’s disease. In X. Huang (Ed.), Alzheimer’s Disease: Drug Discovery. Exon Publications. https://doi.org/10.36255/exonpublications.alzheimersdisease.2020.ch5 sourceSupported

Copper is implicated in cuproptosis, a form of cell death mediated by direct binding of Cu+ to lipoylated DLAT, leading to its aggregation and proteotoxic stress.

“Recent studies also implicate copper in cuproptosis, a novel form of cell death mediated by direct binding of Cu⁺ to lipoylated dihydrolipoyl transacetylase (DLAT), leading to its aggregation and proteotoxic stress [111].”

• cites [111] Feng D, Zhao Y, Li W, Li X, Wan J, Wang F (2023) Copper neurotoxicity: induction of cognitive dysfunction: A review. Medicine (Baltimore) 102(48):e36375. https://doi.org/10.1097/MD.0000000000036375 sourcePartly supported

  Section 3.2 (page not provided) says copper directly binds DLAT, promotes aggregation of lipoylated DLAT, and leads to proteotoxic stress and cuproptosis. It does not identify the directly binding copper as Cu⁺; the Introduction instead describes cuproptosis as triggered by excess Cu²⁺. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Cholinergic dysfunction should be viewed as part of a networked pathology where neurotransmitter, metabolic, inflammatory, and proteostatic processes converge.

“These bidirectional relationships suggest that cholinergic dysfunction should be viewed not in isolation, but as part of a networked pathology where neurotransmitter, metabolic, inflammatory, and proteostatic processes converge [100].”

• cites [100] Pozzi FE, Conti E, Appollonio I, Ferrarese C, Tremolizzo L (2022) Predictors of response to acetylcholinesterase inhibitors in dementia: a systematic review. Front Neurosci 16:998224. https://doi.org/10.3389/fnins.2022.998224 sourcePartly supported

  The Introduction (‘The cholinergic pathways’; page not available) describes cholinergic dysfunction as a common target of interacting factors, including amyloid pathology, tau phosphorylation, and neuroinflammation. The Introduction (‘The cholinergic synapse’; page not available) also discusses cholinergic links to inflammatory pathways. The copy does not establish metabolic pathology as one of the converging processes; its mention of glycolysis concerns acetylcholine synthesis. (LLM, conf=0.83)

  Experimental — accuracy not yet measured

These events culminate in excitotoxic neuronal death, particularly affecting vulnerable regions such as hippocampus and cortex.

“Collectively, these events culminate in excitotoxic neuronal death, particularly affecting vulnerable regions such as the hippocampus and cortex.”

• cites [117] Hou H, Wang L, Fu T, Papasergi M, Yule DI, Xia H (2020) Magnesium acts as a second messenger in the regulation of NMDA receptor-mediated CREB signaling in neurons. Mol Neurobiol 57(6):2539–2550. https://doi.org/10.1007/s12035-020-01871-z sourcePartly supported

  The Introduction links extrasynaptic NMDA receptor signaling and CREB shut-off to glutamate toxicity in ischemic stroke. It does not state that the events culminate in neuronal death or that the hippocampus and cortex are particularly vulnerable; the Methods’ use of cortical neurons does not establish regional vulnerability. No page number is available in our copy. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

Downregulation of PINK1 and PRKN in Alzheimer's disease results in persistence of dysfunctional, ROS-generating mitochondria.

“genes such as PINK1 (encoding for PTEN-induced kinase 1) and PRKN (encoding for 465-amino acid residue E3 ubiquitin ligase), which regulate mitochondrial quality control, are downregulated in AD, resulting in the persistence of dysfunctional, ROS-generating mitochondria [143].”

• cites [143] Du F, Yu Q, Yan SS (2021) PINK1 activation attenuates impaired neuronal-like differentiation and synaptogenesis and mitochondrial dysfunction in Alzheimer’s disease trans-mitochondrial cybrid cells. J Alzheimer’s Dis: JAD 81(4):1749–1761. https://doi.org/10.3233/JAD-210095 sourcePartly supported

  The Discussion (page unavailable) reports reduced PINK1 in AD-affected brains and AD cybrid cells and says insufficient clearance allows dysfunctional mitochondria to persist. The Results (page unavailable) report elevated ROS in AD cybrids that fell with PINK1 activation. The paper does not report PRKN downregulation in AD, so the claim about both genes is not fully supported. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Sporadic Alzheimer's disease is strongly associated with polymorphisms in the APOE gene.

“In contrast, sporadic AD is strongly associated with polymorphisms in the APOE gene.”

• cites [154] Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC (2022) ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol Neurodegener 17(1):72. https://doi.org/10.1186/s13024-022-00574-4 sourceSupported

Dysbiosis-driven production of harmful metabolites such as TMAO from Enterobacteriaceae has been linked to cognitive decline and Aβ aggregation.

“Conversely, dysbiosis-driven production of harmful metabolites (e.g., trimethylamine-N-oxide [TMAO] from Enterobacteriaceae) has been linked to cognitive decline and Aβ aggregation [128].”

• cites [128] Vogt NM, Romano KA, Darst BF, Engelman CD, Johnson SC, Carlsson CM, Asthana S, Blennow K et al (2018) The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease. Alzheimers Res Ther 10(1):124. https://doi.org/10.1186/s13195-018-0451-2 sourcePartly supported

  The Background reports cognitive impairment in mice treated with TMAO, and the Conclusions report elevated CSF TMAO in people with mild cognitive impairment and AD dementia. But the Background and Discussion describe TMAO production as involving gut bacteria and host metabolism, not specifically Enterobacteriaceae or demonstrated dysbiosis-driven production. The Results find no significant association with the Aβ42/Aβ40 measure, and the Discussion does not establish a link to Aβ aggregation. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

A hallmark observation in AD brains is accumulation of autophagic vacuoles in swollen dystrophic neurites, reflecting impaired clearance rather than upregulated initiation.

“A hallmark observation in AD brains is the accumulation of autophagic vacuoles in swollen dystrophic neurites, reflecting impaired clearance rather than upregulated initiation [136].”

• cites [136] Liénard C, Pintart A, Bomont P (2024) Neuronal autophagy: regulations and implications in health and disease. Cells 13(1):103. https://doi.org/10.3390/cells13010103 sourcePartly supported

  Section 3.1 reports that AD brain samples have an abnormal accumulation of immature autophagic vacuoles in dystrophic neurites and says this suggests defective maturation and/or transport. It does not establish impaired clearance as the definitive cause or explicitly rule out upregulated initiation. The reference to swollen axons concerns AD mice, not the described human brain samples; page numbers are unavailable in our copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Clinical studies reveal altered microbial composition in AD patients, often characterized by reduced diversity and depletion of anti-inflammatory commensals.

“Clinical studies reveal altered microbial composition in AD patients, often characterized by reduced diversity and depletion of anti-inflammatory commensals [123].”

• cites [123] Shabbir U, Arshad MS, Sameen A, Oh DH (2021) Crosstalk between gut and brain in Alzheimer’s disease: the role of gut microbiota modulation strategies. Nutrients 13(2):690. https://doi.org/10.3390/nu13020690 sourceSupported

Genetic, biochemical, and imaging studies suggest that the autophagic defect in AD lies not in autophagosome formation but in their maturation and fusion with lysosomes, impairing cargo degradation.

“Genetic, biochemical, and imaging studies suggest that the defect lies not in autophagosome formation but in their maturation and fusion with lysosomes, impairing cargo degradation [136].”

• cites [136] Liénard C, Pintart A, Bomont P (2024) Neuronal autophagy: regulations and implications in health and disease. Cells 13(1):103. https://doi.org/10.3390/cells13010103 sourcePartly supported

  Section 3.1 reports immature autophagic vesicles in AD brain samples and says this suggests a defect in their maturation and/or transport. Section 2.3 explains that fusion with lysosomes enables cargo degradation, but the AD passage does not establish fusion failure specifically. Section 4.4 also mentions failed autophagosome formation in dementia symptoms present in AD, so the claim’s exclusion of formation defects is not supported. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Circulating proinflammatory mediators cross a compromised BBB and trigger microglial activation, fueling neuroinflammation.

“Moreover, circulating proinflammatory mediators cross a compromised BBB and trigger microglial activation, fueling neuroinflammation [89].”

• cites [89] Sun Z, Zhang X, So K-F, Jiang W, Chiu K (2024) Targeting microglia in Alzheimer’s disease: pathogenesis and potential therapeutic strategies. Biomolecules 14(7):833. https://doi.org/10.3390/biom14070833 sourcePartly supported

  Section 3.2, Table 2, mentions blood–brain barrier leakiness, and Section 3.2 links activated microglia to neuroinflammation. Neither passage says that circulating proinflammatory mediators cross a compromised barrier and trigger microglial activation; the section instead describes aggregated Aβ as a trigger. (LLM, conf=0.83)

  Experimental — accuracy not yet measured

Impaired mitophagy hinders removal of dysfunctional mitochondria, worsening oxidative stress and metabolic failure.

“First, impaired mitophagy hinders the removal of dysfunctional mitochondria, worsening oxidative stress and metabolic failure [138].”

• cites [138] Lyu Y, Meng Z, Hu Y, Jiang B, Yang J, Chen Y, Zhou J, Li M et al (2024) Mechanisms of mitophagy and oxidative stress in cerebral ischemia-reperfusion, vascular dementia, and Alzheimer’s disease. Front Mol Neurosci 17:1394932. https://doi.org/10.3389/fnmol.2024.1394932 sourceSupported

The gut microbiota plays critical roles in metabolism, immune regulation, and neural signaling.

“The gut microbiota, consisting primarily of bacteria but also fungi, viruses, archaea, and protozoa, plays critical roles in metabolism, immune regulation, and neural signaling.”

• cites [122] Malan-Müller S, Martín-Hernández D, Caso JR, Matthijnssens J, Rodríguez-Urrutia A, Lowry CA, Leza JC (2025) Metagenomic symphony of the intestinal ecosystem: how the composition affects the mind. Brain Behav Immun 123:510–523. https://doi.org/10.1016/j.bbi.2024.09.033 sourceSupported

Protective variants such as APOE3ch underscore the nuanced, isoform-specific effects of ApoE on Alzheimer's disease trajectory.

“The discovery of protective variants such as APOE3ch underscores the nuanced, isoform-specific effects of ApoE on disease trajectory [155].”

• cites [155] Sepulveda-Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta-Uribe J, Vila-Castelar C, Ramirez-Gomez L, Baena A et al (2022) Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia. Acta Neuropathol 144(3):589–601. https://doi.org/10.1007/s00401-022-02467-8 sourceSupported

Glial autophagy, particularly in microglia and astrocytes, regulates synaptic pruning and Aβ clearance.

“Glial autophagy, particularly in microglia and astrocytes, regulates synaptic pruning and Aβ clearance; its impairment may shift glia toward proinflammatory phenotypes [142].”

• cites [142] Lieberman OJ, McGuirt AF, Tang G, Sulzer D (2019) Roles for neuronal and glial autophagy in synaptic pruning during development. Neurobiol Dis 122:49–63. https://doi.org/10.1016/j.nbd.2018.04.017 sourcePartly supported

  Sections VII–VIII support a role for microglial autophagy in synaptic pruning, and Section II describes astrocytes engulfing synapses during pruning. The cited passages do not establish that astrocyte autophagy regulates pruning or that glial autophagy clears Aβ. They also do not support the citing sentence’s claim that impaired glial autophagy shifts glia toward proinflammatory phenotypes. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Pathogens may act as environmental triggers for Alzheimer's disease through direct cytotoxicity, in which pathogens infect central nervous system cells, leading to neuronal injury, cell death, and release of DAMPs that initiate chronic inflammation.

“The first posits direct cytotoxicity, in which pathogens infect central nervous system cells, leading to neuronal injury, cell death, and the release of damage-associated molecular patterns (DAMPs) that initiate chronic inflammation [164].”

• cites [164] Catumbela CSG, Giridharan VV, Barichello T et al (2023) Clinical evidence of human pathogens implicated in Alzheimer’s disease pathology and the therapeutic efficacy of antimicrobials: an overview. Transl Neurodegener 12:37. https://doi.org/10.1186/s40035-023-00369-7 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

PINK1 and PRKN are downregulated in Alzheimer's disease.

“genes such as PINK1 (encoding for PTEN-induced kinase 1) and PRKN (encoding for 465-amino acid residue E3 ubiquitin ligase), which regulate mitochondrial quality control, are downregulated in AD, resulting in the persistence of dysfunctional, ROS-generating mitochondria [143].”

• cites [143] Du F, Yu Q, Yan SS (2021) PINK1 activation attenuates impaired neuronal-like differentiation and synaptogenesis and mitochondrial dysfunction in Alzheimer’s disease trans-mitochondrial cybrid cells. J Alzheimer’s Dis: JAD 81(4):1749–1761. https://doi.org/10.3233/JAD-210095 sourcePartly supported

  The Results section, “Decreased PINK1 level in the differentiated AD cybrid cells” (page unavailable), reports 50–60% lower PINK1 expression in AD cybrids than in non-AD cells. The paper does not report that PRKN is downregulated in AD, so the claim is supported for PINK1 but not PRKN. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Dysbiosis has been increasingly associated with AD.

“Dysbiosis, or microbial imbalance, has been increasingly associated with AD.”

• cites [123] Shabbir U, Arshad MS, Sameen A, Oh DH (2021) Crosstalk between gut and brain in Alzheimer’s disease: the role of gut microbiota modulation strategies. Nutrients 13(2):690. https://doi.org/10.3390/nu13020690 sourceSupported

Microbial biomarkers, including specific taxa such as Bacteroides fragilis and metabolite signatures such as elevated TMAO, may serve as non-invasive diagnostic tools for early AD detection.

“Microbial biomarkers, including specific taxa (e.g., Bacteroides fragilis) and metabolite signatures (e.g., elevated TMAO), may also serve as non-invasive diagnostic tools for early AD detection [132].”

• cites [132] Xia Y, Xiao Y, Wang ZH, Liu X, Alam AM, Haran JP, McCormick BA, Shu X et al (2023) Bacteroides fragilis in the gut microbiomes of Alzheimer’s disease activates microglia and triggers pathogenesis in neuronal C/EBPβ transgenic mice. Nat Commun 14(1):5471. https://doi.org/10.1038/s41467-023-41283-w sourcePartly supported

  The Discussion reports higher Bacteroides abundance in the AD patient cohort and identifies B. fragilis as a prominent strain; the Results also find it enriched in mice receiving AD fecal transplants. The paper does not establish B. fragilis as a non-invasive tool for early diagnosis, and searches for TMAO and diagnostic biomarkers found no support for the elevated-TMAO example. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Trehalose, spermidine, and resveratrol have been explored for their ability to stimulate autophagy and mitophagy with relative safety.

“Small molecules such as trehalose, spermidine, and resveratrol have been explored for their ability to stimulate autophagy and mitophagy with relative safety [145, 146].”

• cites [145] Korolenko TA, Dubrovina NI, Ovsyukova MV, Bgatova NP, Tenditnik MV, Pupyshev AB, Akopyan AA, Goncharova NV et al (2021) Treatment with autophagy inducer trehalose alleviates memory and behavioral impairments and neuroinflammatory brain processes in db/db mice. Cells 10(10):2557. https://doi.org/10.3390/cells10102557 sourcePartly supported

  The Discussion (page unavailable) identifies trehalose, spermidine, and resveratrol as compounds associated with restored autophagy that processes dysfunctional mitochondria. The Introduction calls trehalose nontoxic, but the paper does not establish relative safety for spermidine or resveratrol, or specifically show that all three stimulate mitophagy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [146] Panda PK, Fahrner A, Vats S, Seranova E, Sharma V, Chipara M, Desai P, Torresi J et al (2019) Chemical screening approaches enabling drug discovery of autophagy modulators for biomedical applications in human diseases. Front Cell Dev Biol 7:38. https://doi.org/10.3389/fcell.2019.00038 sourcePartly supported

  The sections on neurodegenerative diseases and lifespan extension describe trehalose, spermidine, and resveratrol as autophagy inducers explored in experimental models. They do not establish that all three stimulate mitophagy or have relative safety, so those parts of the claim are unsupported by this source. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Communication between gut and brain occurs through multiple interconnected neural, endocrine, immune, and metabolic pathways that can synergize to modulate AD risk and progression.

“Communication between the gut and brain occurs through multiple, interconnected pathways, including neural, endocrine, immune, and metabolic routes, that can synergize to modulate AD risk and progression [122].”

• cites [122] Malan-Müller S, Martín-Hernández D, Caso JR, Matthijnssens J, Rodríguez-Urrutia A, Lowry CA, Leza JC (2025) Metagenomic symphony of the intestinal ecosystem: how the composition affects the mind. Brain Behav Immun 123:510–523. https://doi.org/10.1016/j.bbi.2024.09.033 sourcePartly supported

  Section 2.1 (pp. 3–4) describes bidirectional gut–brain communication through neural, endocrine, immune, and microbial-metabolite routes. The discussion on p. 5 links herpes infections in the brain to Alzheimer’s disease risk and progression, but does not establish that the listed gut–brain pathways act synergistically to modulate that risk or progression. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Chronic or repeated infections overwhelm clearance mechanisms, resulting in persistent protein aggregation and neuroinflammation that ultimately drive neurodegeneration.

“While protective in the short term, chronic or repeated infections overwhelm clearance mechanisms, resulting in persistent protein aggregation and neuroinflammation that ultimately drive neurodegeneration [165].”

• cites [165] Nasb M, Tao W, Chen N (2024) Alzheimer’s disease puzzle: delving into pathogenesis hypotheses. Aging and disease 15(1):43–73. https://doi.org/10.14336/AD.2023.0608 sourcePartly supported

  The sections on the intersection of AD hypotheses and pro-inflammatory cytokines describe impaired Aβ clearance, accumulating aggregates, self-perpetuating neuroinflammation, and neuronal damage (page not provided). They do not say that chronic or repeated infections overwhelm clearance mechanisms, nor do they establish the claimed short-term protective response. The paper also notes in “Role of inflammation in AD” that whether inflammation is a cause or consequence remains unclear. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Mitophagy failure is emerging as a central theme in Alzheimer's disease.

“Furthermore, mitophagy failure is emerging as a central theme, whereby genes such as PINK1 (encoding for PTEN-induced kinase 1) and PRKN (encoding for 465-amino acid residue E3 ubiquitin ligase), which regulate mitochondrial quality control, are downregulated in AD, resulting in the persistence of dysfunctional, ROS-generating mitochondria [143].”

• cites [143] Du F, Yu Q, Yan SS (2021) PINK1 activation attenuates impaired neuronal-like differentiation and synaptogenesis and mitochondrial dysfunction in Alzheimer’s disease trans-mitochondrial cybrid cells. J Alzheimer’s Dis: JAD 81(4):1749–1761. https://doi.org/10.3233/JAD-210095 sourcePartly supported

  The Discussion (page not provided) describes insufficient clearance of defective mitochondria in AD and says PINK1-mediated mitophagy helps eliminate them. The Results report reduced PINK1 expression in AD cybrid cells and elevated ROS, but the paper does not establish that PRKN is also downregulated in AD. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Jamieson et al. in 1991 identified Herpes Simplex Virus type 1 DNA in Alzheimer's disease brains.

“First hinted at by Oskar Fischer in 1907 and later substantiated by Jamieson et al. in 1991, who identified Herpes Simplex Virus type 1 (HSV-1) DNA in AD brains, the idea that infections contribute to AD pathogenesis has steadily gained traction over the past three decades [162].”

• cites [162] Naughton SX, Raval U, Pasinetti GM (2020) The viral hypothesis in Alzheimer’s disease: novel insights and pathogen-based biomarkers. J Pers Med 10(3):74. https://doi.org/10.3390/jpm10030074 sourceCould not verify

  Section 2.1 discusses herpesviruses in Alzheimer’s disease brains, but does not say that Jamieson et al. identified HSV-1 DNA there in 1991. Searches for Jamieson, 1991, and the claimed HSV-1 DNA finding found no passage addressing that specific attribution. (LLM, conf=0.70)

  Experimental — accuracy not yet measured

Impairment of glial autophagy may shift glia toward proinflammatory phenotypes.

“Glial autophagy, particularly in microglia and astrocytes, regulates synaptic pruning and Aβ clearance; its impairment may shift glia toward proinflammatory phenotypes [142].”

• cites [142] Lieberman OJ, McGuirt AF, Tang G, Sulzer D (2019) Roles for neuronal and glial autophagy in synaptic pruning during development. Neurobiol Dis 122:49–63. https://doi.org/10.1016/j.nbd.2018.04.017 sourceCould not verify

  Section V says peripheral inflammatory insults can inhibit autophagic function in the brain, but does not say that impaired glial autophagy shifts glia toward proinflammatory phenotypes. Sections VII–VIII discuss microglial autophagy in synaptic pruning without addressing that proposed shift. Searches for proinflammatory phenotypes and inflammatory responses to impaired microglial autophagy found no supporting passage. (LLM, conf=0.73)

  Experimental — accuracy not yet measured

Numerous viral and bacterial agents, including herpesviruses, flaviviruses, HIV, hepatitis viruses, Borna virus, Ljungan virus, and influenza A virus, have been linked to an increased risk of Alzheimer's disease.

“Since then, numerous viral and bacterial agents, including herpesviruses, flaviviruses, human immunodeficiency virus (HIV), hepatitis viruses, Borna virus, Ljungan virus, and influenza A virus, have been linked to an increased risk of AD [163].”

• cites [163] Bocharova OV, Fisher A, Pandit NP, Molesworth K, Mychko O, Scott AJ, Makarava N, Ritzel R, et al. (2022) Aβ plaques do not protect against HSV-1 infection in a mouse model of familial Alzheimer’s disease, and HSV-1 does not induce Aβ pathology in a model of late onset Alzheimer’s disease. Brain Pathol 33:e13116. https://doi.org/10.1111/bpa.13116 sourcePartly supported

  The Introduction and Discussion (pages unavailable) describe herpesviruses as pathogens linked to late-onset Alzheimer’s disease, while noting that the association is controversial. The paper does not identify flaviviruses, HIV, hepatitis viruses, Borna virus, Ljungan virus, or influenza A virus as linked to increased Alzheimer’s risk, so it supports only part of the cited list. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

PSEN1 mutations disrupt γ-secretase assembly and function, skewing APP cleavage toward longer, aggregation-prone Aβ42 fragments.

“These mutations disrupt γ-secretase assembly and function, skewing APP cleavage toward longer, aggregation-prone Aβ42 fragments [148, 149].”

• cites [148] Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P, Vargas-Rodríguez I, Cadena-Suárez AR, Sánchez-Garibay C, Pozo-Molina G, Méndez-Catalá CF et al (2023) Alzheimer’s disease: an updated overview of its genetics. Int J Mol Sci 24(4):3754. https://doi.org/10.3390/ijms24043754 sourcePartly supported

  Section 2, “The Four Classical Genes Associated with Alzheimer’s Disease” (page unavailable), says PSEN mutations interfere with the γ-secretase complex and alter APP processing, increasing the Aβ42/Aβ40 ratio. It does not specifically describe Aβ42 as aggregation-prone, so that part of the attributed claim is not supported by our copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [149] Xiao X, Liu H, Liu X, Zhang W, Zhang S, Jiao B (2021) APP, PSEN1, and PSEN2 variants in Alzheimer’s disease: systematic re-evaluation according to ACMG guidelines. Front Aging Neurosci 13:695808. https://doi.org/10.3389/fnagi.2021.695808 sourcePartly supported

  The Introduction (page not provided) says PSEN1 is a γ-secretase subunit and associates presenilins with an increased Aβ42-to-Aβ40 ratio. The Discussion (page not provided) links PSEN1 to γ-secretase activity and APP processing. Neither passage says PSEN1 mutations disrupt γ-secretase assembly or describes Aβ42 as longer and aggregation-prone. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Therapeutic innovation in Alzheimer's disease is increasingly moving toward immune rebalancing and metabolic reprogramming.

“Therapeutic innovation is increasingly moving toward immune rebalancing and metabolic reprogramming [179].”

• cites [179] Sangineto M, Ciarnelli M, Cassano T, Radesco A, Moola A, Bukke VN, Romano A, Villani R et al (2023) Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer’s disease. Redox Biol 66:102846. https://doi.org/10.1016/j.redox.2023.102846 sourcePartly supported

  The Discussion identifies microglial metabolic reprogramming as a promising way to control inflammation in early Alzheimer's disease, and the Results report a shift in inflammatory markers after metabolic intervention in mice. The paper does not establish that therapeutic innovation is increasingly moving in this direction across the field; it also finds this approach ineffective in advanced disease. Page numbers were not provided in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

An APOE4 carrier with chronic herpesvirus reactivation may traverse the resilience threshold much earlier than an APOE3 carrier with preserved mitochondrial reserve, despite similar amyloid burdens.

“For instance, an APOE4 carrier with chronic herpesvirus reactivation may traverse the threshold much earlier than an APOE3 carrier with preserved mitochondrial reserve, despite similar amyloid burdens [171].”

• cites [171] Wei P, Lin K, Chen X, Fang C, Qiu L, Hu J, Chang J (2025) Sequential proteomic analysis reveals the key APOE4-induced pathological and molecular features at the presymptomatic stage in Alzheimer’s disease mice. CNS Neurosci Ther 31(3):e70306. https://doi.org/10.1111/cns.70306 sourcePartly supported

  The Results section (page unavailable) reports impaired mitochondrial function with APOE4 versus APOE3 in mouse neuronal cells, and the Introduction associates APOE4 with earlier Alzheimer’s onset. The paper does not examine herpesvirus reactivation or a resilience threshold, and its Results report greater—not similar—amyloid deposition in APOE4 mice. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Neuroinflammatory readouts such as soluble TREM2, YKL-40, or inflammasome-derived products may provide insight into the immune component of Alzheimer's disease progression.

“Neuroinflammatory readouts such as soluble TREM2, YKL-40, or inflammasome-derived products (e.g., caspase-1 cleavage fragments) may provide insight into the immune component of disease progression [172, 173].”

• cites [172] Tan MS, Liu Y, Hu H, Tan CC, Tan L (2022) Inhibition of caspase-1 ameliorates tauopathy and rescues cognitive impairment in SAMP8 mice. Metab Brain Dis 37(4):1197–1205. https://doi.org/10.1007/s11011-022-00914-9 sourceNot checked — no full text of the source
• cites [173] Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, et al. (2017) YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener 12(1):83. https://doi.org/10.1186/s13024-017-0226-4 sourcePartly supported

  The Discussion reports elevated YKL-40 in early Alzheimer’s disease and describes YKL-40 measurement as potentially useful for detecting early neuroinflammatory changes. It does not substantiate the sentence’s other examples—soluble TREM2 or inflammasome-derived products such as caspase-1 cleavage fragments—as readouts of disease progression. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Circulating exosomes containing Aβ, tau, and inflammasome components represent a promising avenue for minimally invasive biomarker discovery, as they may mirror central nervous system processes in peripheral fluids.

“Circulating exosomes containing Aβ, tau, and inflammasome components also represent a promising avenue for minimally invasive biomarker discovery, as they may mirror central nervous system processes in peripheral fluids [174].”

• cites [174] Badhwar A, Haqqani AS (2020) Biomarker potential of brain-secreted extracellular vesicles in blood in Alzheimer’s disease. Alzheimer’s Dement (Amsterdam, Netherlands) 12(1):e12001. https://doi.org/10.1002/dad2.12001 sourcePartly supported

  The Introduction (page not provided) describes blood-accessible extracellular vesicles as carrying tissue-specific cargo that reflects the originating cells’ physiological state. Section 6, Conclusions (page not provided), discusses Aβ42 and tau in blood-isolated brain-derived vesicles as potential Alzheimer’s biomarkers, while noting inconsistent findings for tau. The copy does not identify inflammasome components as part of this biomarker avenue. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

The mechanisms of AD are not discrete but form a highly interconnected network.

“Mounting evidence indicates that these mechanisms are not discrete but instead form a highly interconnected network.”

Disruption of the balance between Aβ production and elimination, rather than overproduction alone, appears central to sporadic late-onset AD.

“Disruption of this equilibrium, rather than overproduction alone, appears central to sporadic late-onset AD.”

No single hypothesis is sufficient in isolation to explain the full complexity of AD.

“Although each hypothesis offers valuable perspectives, none is sufficient in isolation to explain the full complexity of AD.”

The loss-of-function perspective of Aβ provides a mechanistic bridge linking early synaptic dysregulation and glial activation to mitochondrial, metabolic, and inflammatory cascades that drive progressive neurodegeneration.

“Within the broader integrative framework proposed in this review, this loss-of-function perspective provides a mechanistic bridge linking early synaptic dysregulation and glial activation to mitochondrial, metabolic, and inflammatory cascades that drive progressive neurodegeneration.”

Prion-like transcellular propagation of tau pathology may underlie the stereotypical spatiotemporal progression of AD neuropathology described by Braak staging.

“This prion-like transcellular propagation of tau pathology may underlie the stereotypical spatiotemporal progression of AD neuropathology described by Braak staging [46, 47].”

• cites [46] Macedo AC, Durço DFPA, Tissot C, Therriault J, de Vilela Faria AO, Aumont É, Servaes S, Rahmouni N et al (2024) Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer’s Disease. J Prev Alzheimer’s Dis 11(2):414–421. https://doi.org/10.14283/jpad.2024.15 sourceNot checked — no full text of the source
• cites [47] Brunnström H, Englund E (2011) Comparison of four neuropathological scales for Alzheimer’s disease. Clin Neuropathol 30(2):56–69. https://doi.org/10.5414/npp30056 sourceNot checked — no full text of the source

The limited clinical efficacy, high cost, and safety concerns of anti-Aβ monoclonal antibodies underscore the limitations of a single-target therapeutic paradigm.

“However, their limited clinical efficacy, high cost, and considerable safety concerns underscore the persistent limitations of a single-target therapeutic paradigm.”

Dysregulation of the balance between tau kinases and phosphatases favors accumulation of hyperphosphorylated tau.

“Dysregulation of this balance favors the accumulation of hyperphosphorylated tau.”

Excessive GSK-3 activity is proposed to underlie the synergistic interaction between amyloid and tau pathologies.

“Excessive GSK-3 activity is proposed to underlie the synergistic interaction between amyloid and tau pathologies, linking the two central hypotheses of AD.”

Dysregulation of metal homeostasis, particularly iron, copper, and zinc, is implicated in amyloid aggregation and oxidative injury in AD.

“Dysregulation of metal homeostasis, particularly iron, copper, and zinc, has been implicated in both amyloid aggregation and oxidative injury [14, 15].”

• cites [14] Althobaiti NA (2025) Heavy metals exposure and Alzheimer’s disease: underlying mechanisms and advancing therapeutic approaches. Behav Brain Res 476:115212. https://doi.org/10.1016/j.bbr.2024.115212 sourceNot checked — no full text of the source
• cites [15] Adlard PA, Bush AI (2006) Metals and Alzheimer’s disease. J Alzheimer’s Dis: JAD 10(2–3):145–163. https://doi.org/10.3233/jad-2006-102-303 sourceNot checked — no full text of the source

The amyloid cascade hypothesis has evolved to a framework where Aβ serves as a key upstream trigger but functions within a broader interconnected network of disease processes.

“Taken together, the amyloid cascade hypothesis has evolved from a straightforward, amyloid-focused model to a more comprehensive framework, where Aβ serves as a key upstream trigger but functions within a broader, interconnected network of disease processes.”

Neuroinflammation is a central hub that modulates both amyloid and tau pathology.

“For example, neuroinflammation is increasingly understood as a central hub that modulates both amyloid and tau pathology [21], while mitochondrial failure and impaired autophagy act as amplifiers of proteotoxic stress [22].”

• cites [21] Calsolaro V, Edison P (2016) Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement 12(6):719–732. https://doi.org/10.1016/j.jalz.2016.02.010 sourceNot checked — no full text of the source

Genetic risk factors for AD often map onto pathways that intersect these processes, suggesting shared nodes of vulnerability.

“Genetic risk factors often map onto pathways that intersect these processes, suggesting shared nodes of vulnerability.”

α-Synuclein, heat shock proteins, immunophilins, and Pin1 regulate tau phosphorylation, aggregation, or degradation.

“Besides, crosstalk with other proteins adds additional complexity; for example, α-synuclein, heat shock proteins, immunophilins, and the prolyl isomerase 1 (Pin1) have all been shown to regulate tau phosphorylation, aggregation, or degradation [48, 52].”

• cites [48] Zhao Y, Kuca K, Wu W, Wang X, Nepovimova E, Musilek K, Wu Q (2022) Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases. Alzheimers Dement 18(1):152–158. https://doi.org/10.1002/alz.12370 sourceNot checked — no full text of the source
• cites [52] Muralidar S, Ambi SV, Sekaran S, Thirumalai D, Palaniappan B (2020) Role of tau protein in Alzheimer’s disease: the prime pathological player. Int J Biol Macromol 163:1599–1617. https://doi.org/10.1016/j.ijbiomac.2020.07.327 sourceNot checked — no full text of the source

Pathological, genetic, and clinical evidence points to multiple interconnected processes converging on neurodegeneration in AD.

“Pathological, genetic, and clinical evidence now points to a more intricate landscape, where multiple interconnected processes converge on neurodegeneration.”

Oxidative stress and mitochondrial impairment are central amplifiers of cellular injury in AD.

“Cholinergic dysfunction has long been recognized as a correlate of cognitive decline, while oxidative stress and mitochondrial impairment are increasingly appreciated as central amplifiers of cellular injury [12, 13].”

• cites [12] Aliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, Ashraf GM, Jabir NR et al (2014) Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr Med Chem 21(19):2208–2217. https://doi.org/10.2174/0929867321666131227161303 sourceNot checked — no full text of the source
• cites [13] Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306(3):821–827. https://doi.org/10.1124/jpet.102.041616 sourceNot checked — no full text of the source

This perspective offers a unifying explanation for why pathological changes such as NFTs or amyloid plaques are regionally selective and temporally progressive.

“This perspective offers a unifying explanation for why pathological changes, such as NFTs or amyloid plaques, are regionally selective and temporally progressive, or, in short, they emerge where maladaptive responses are most pronounced.”

• AssumptionRests on an assumption: In AD, synaptic dysfunction occurs early, often preceding measurable neuronal loss.
• AssumptionRests on an assumption: Age, genetic variants such as APOE4, and epigenetic modifications modulate the thresholds for synaptic plasticity.

Mitochondria may represent a central hub where amyloid, tau, and neuroinflammatory pathways converge.

“This reciprocal amplification suggests that mitochondria may represent a central hub where amyloid, tau, and neuroinflammatory pathways converge.”

The maladaptive synaptoplasticity framework reframes AD not merely as a disease of protein aggregation, but as a disorder of circuit-level homeostasis and network remodeling.

“Importantly, the maladaptive synaptoplasticity framework reframes AD not merely as a disease of protein aggregation, but as a disorder of circuit-level homeostasis and network remodeling.”

• AssumptionRests on an assumption: In AD, synaptic dysfunction occurs early, often preceding measurable neuronal loss.
• AssumptionRests on an assumption: Age, genetic variants such as APOE4, and epigenetic modifications modulate the thresholds for synaptic plasticity.

Both glucose hypometabolism on FDG-PET and increased oxidative biomarkers in brain and CSF represent functional readouts of mitochondrial bioenergetic collapse rather than separate processes.

“Moreover, both glucose hypometabolism detected on fludeoxyglucose F18 (FDG)-positron emission tomography (PET) (FDG-PET) and increased oxidative biomarkers in the brain and CSF represent functional readouts of mitochondrial bioenergetic collapse rather than separate processes.”

Immune dysregulation is not merely a reaction to pathology but a genetically encoded contributor to disease progression.

“These findings emphasize that immune dysregulation is not merely a reaction to pathology but a genetically encoded contributor to disease progression.”

Bidirectional communication establishes a self-reinforcing exosome-inflammasome loop, providing a plausible explanation for how focal protein aggregation expands across distributed brain networks in parallel with disease progression.

“This bidirectional communication establishes a self-reinforcing exosome–inflammasome loop, providing a plausible explanation for how focal protein aggregation expands across distributed brain networks in parallel with disease progression.”

Tau pathology is not merely downstream of amyloid but is itself a central driver of neuronal dysfunction.

“Taken together, the tau hypothesis provides compelling evidence that tau pathology is not merely downstream of amyloid but is itself a central driver of neuronal dysfunction.”

In AD, the adaptive process of neuroplasticity appears to become maladaptive, contributing to neurodegeneration.

“In AD, however, this adaptive process appears to become maladaptive, contributing to neurodegeneration.”

Chronic neuroinflammation amplifies both Aβ and tau pathology.

“Importantly, chronic neuroinflammation does not simply coexist with Aβ and tau pathology; it amplifies both.”

APOE4 and hyperactive GSK-3β further promote both mitochondrial dysfunction and proteotoxic accumulation.

“Consistent with this view, the presence of APOE4 and hyperactive GSK-3β, well-established AD risk factors, further promotes both mitochondrial dysfunction and proteotoxic accumulation [65], illustrating the integrated nature of these hypotheses.”

• cites [65] Zhou M, Huang T, Collins N, Zhang J, Shen H, Dai X, Xiao N, Wu X et al (2016) APOE4 induces site-specific tau phosphorylation through calpain-CDK5 signaling pathway in EFAD-Tg mice. Curr Alzheimer Res 13(9):1048–1055. https://doi.org/10.2174/1567205013666160415154550 sourceNot checked — no full text of the source

Tauopathy must be viewed within a broader, multi-hit framework rather than as an isolated pathway.

“The intimate interplay between Aβ, tau, and neuroinflammation suggests that tauopathy must be viewed within a broader, multi-hit framework rather than as an isolated pathway.”

Metabolic dysregulation in AD reflects a complex interplay between glucose transport deficits, mitochondrial dysfunction, oxidative stress, and chronic inflammation.

“Taken together, metabolic dysregulation in AD reflects more than passive energy failure; it represents a complex interplay between glucose transport deficits, mitochondrial dysfunction, oxidative stress, and chronic inflammation.”

The relationship between mitochondrial dysfunction and canonical AD pathologies is bidirectional.

“Furthermore, the relationship between mitochondrial dysfunction and canonical AD pathologies is bidirectional.”

Mitochondrial dysfunction underlies and unites both cerebral hypometabolism and oxidative stress observed in AD.

“Importantly, mitochondrial dysfunction underlies and unites both cerebral hypometabolism and oxidative stress observed in AD.”

Glucose hypometabolism limits the bioenergetic capacity of glia to maintain protein clearance, predisposing them to proinflammatory states.

“Metabolic dysregulation, particularly glucose hypometabolism, limits the bioenergetic capacity of glia to maintain protein clearance, predisposing them to proinflammatory states.”

Excitotoxicity represents a convergence point linking synaptoplasticity, mitochondrial failure, oxidative stress, and neuroinflammation.

“Thus, excitotoxicity represents a convergence point linking synaptoplasticity, mitochondrial failure, oxidative stress, and neuroinflammation.”

Copper dyshomeostasis links proteostatic collapse with mitochondrial and metabolic dysfunction.

“Copper dyshomeostasis, therefore, links proteostatic collapse with mitochondrial and metabolic dysfunction.”

The metal ion hypothesis represents not an isolated mechanism but an integrative pathway that converges with amyloid, tau, mitochondrial, oxidative, and inflammatory cascades.

“Thus, the metal ion hypothesis represents not an isolated mechanism but an integrative pathway that converges with amyloid, tau, mitochondrial, oxidative, and inflammatory cascades (Fig. 7).”

The glutamatergic excitotoxicity hypothesis underscores dysregulated neurotransmission as a key pathogenic driver in AD.

“Taken together, the glutamatergic excitotoxicity hypothesis underscores the role of dysregulated neurotransmission as a key pathogenic driver in AD.”

Excess ROS promotes amyloidogenic processing of APP by modulating secretase activity, thereby increasing Aβ production.

“Excess ROS promotes amyloidogenic processing of APP by modulating secretase activity, thereby increasing Aβ production.”

Oxidative stress intersects with nearly all major pathogenic hypotheses of AD.

“Moreover, oxidative stress does not act in isolation but intersects with nearly all major pathogenic hypotheses of AD.”

Interplay between excitatory and inhibitory neurotransmitter systems, particularly dysregulation of GABA, may further tip balance toward hyperexcitability and network dysfunction in AD.

“Moreover, the interplay between excitatory and inhibitory neurotransmitter systems, particularly the dysregulation of γ-aminobutyric acid (GABA), may further tip the balance toward hyperexcitability and network dysfunction in AD [121].”

• cites [121] Carello-Collar G, Bellaver B, Ferreira PCL, Ferrari-Souza JP, Ramos VG, Therriault J, Tissot C, Bastiani MA et al (2023) The GABAergic system in Alzheimer’s disease: a systematic review with meta-analysis. Mol Psychiatry 28(12):5025–5036. https://doi.org/10.1038/s41380-023-02140-w sourceNot checked — no full text of the source

ROS and lipid peroxidation products enhance tau phosphorylation through kinase activation, accelerating NFT formation.

“In parallel, ROS and lipid peroxidation products enhance tau phosphorylation through kinase activation, accelerating the formation of NFTs.”

Neuroinflammation is the point of network convergence, integrating mitochondrial, metabolic, and synaptoplasticity disturbances into a unified pathogenic cascade.

“These interactions highlight neuroinflammation as the point of network convergence, integrating mitochondrial, metabolic, and synaptoplasticity disturbances into a unified pathogenic cascade.”

Mitochondria are the dominant source of ROS in neurons, particularly through electron leakage at complexes I and III of the electron transport chain.

“Mitochondria are the dominant source of ROS in neurons, particularly through electron leakage at complexes I and III of the electron transport chain.”

Oxidative stress functions as a nexus, bridging mitochondrial dysfunction, metabolic failure, neuroinflammation, and proteostatic collapse in AD pathogenesis.

“Thus, oxidative stress functions as a nexus, bridging mitochondrial dysfunction, metabolic failure, neuroinflammation, and proteostatic collapse in AD pathogenesis.”

Memantine's limited efficacy highlights challenges of neurotransmitter-based interventions in multifactorial disorders.

“However, its limited efficacy highlights the challenges of neurotransmitter-based interventions in multifactorial disorders.”

Zinc imbalance can exacerbate both amyloid and synaptoplasticity dysfunctions.

“Thus, zinc imbalance can exacerbate both amyloid and synaptoplasticity dysfunctions.”

Oxidative stress is not merely a byproduct of AD but a pivotal driver that integrates and amplifies other pathogenic processes.

“Taken together, oxidative stress is not merely a byproduct of AD but a pivotal driver that integrates and amplifies other pathogenic processes.”

The metal ion hypothesis underscores the importance of ionic homeostasis in AD pathogenesis.

“Taken together, the metal ion hypothesis underscores the importance of ionic homeostasis in AD pathogenesis.”

Suppressing inflammation broadly risks eliminating protective glial functions.

“Such failures underscore the inadequacy of suppressing inflammation broadly, which risks eliminating protective glial functions.”

Classical antioxidants vitamin E, selegiline, and coenzyme Q10 have not demonstrated consistent cognitive benefit in AD patients, even when combined with cholinesterase inhibitors.

“Classical agents such as vitamin E, selegiline, and coenzyme Q10 have not demonstrated consistent cognitive benefit in patients, even when combined with cholinesterase inhibitors [104].”

• cites [104] Rijpma A, Meulenbroek O, Olde Rikkert MG (2014) Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer’s disease: a systematic review of randomized controlled trials. Ageing Res Rev 16:105–112. https://doi.org/10.1016/j.arr.2014.06.002 sourceNot checked — no full text of the source

The infectious hypothesis of Alzheimer's disease has re-emerged as a compelling framework supported by evidence linking microbial pathogens to Aβ deposition, neuroinflammation, and cognitive decline.

“The infectious hypothesis of AD has re-emerged as a compelling framework, supported by evidence linking microbial pathogens to Aβ deposition, neuroinflammation, and cognitive decline.”

Genetic discoveries provide a unifying lens through which the major pathogenic hypotheses of Alzheimer's disease can be contextualized.

“Rather than representing a distinct mechanism, genetic discoveries provide a unifying lens through which the major pathogenic hypotheses of AD can be contextualized.”

In AD, autophagy becomes dysfunctional at multiple levels, transforming from a protective process into a pathogenic one.

“In AD, mounting evidence indicates that autophagy becomes dysfunctional at multiple levels, transforming from a protective process into a pathogenic one.”

The microbiota-gut-brain axis is a compelling framework for understanding how peripheral systems influence central neurodegeneration in AD.

“The microbiota–gut–brain axis has emerged as a compelling framework for understanding how peripheral systems influence central neurodegeneration in AD.”

Autophagy dysfunction is increasingly recognized as a unifying pathogenic mechanism in Alzheimer's disease, sitting at the intersection of proteinopathy, mitochondrial failure, and neuroinflammation.

“In summary, autophagy dysfunction is increasingly recognized as a unifying pathogenic mechanism in AD, sitting at the intersection of proteinopathy, mitochondrial failure, and neuroinflammation.”

The most definitive evidence for causality in Alzheimer's disease comes from autosomal dominant familial AD mutations in PSEN1, PSEN2, and APP.

“The most definitive evidence for causality comes from autosomal dominant FAD mutations in the PSEN1, PSEN2, and APP genes (Table 1).”

The microbiota-gut-brain axis hypothesis positions the gut as an active regulator of neurodegenerative processes.

“In summary, the microbiota–gut–brain axis hypothesis positions the gut as an active regulator of neurodegenerative processes.”

By linking specific microbial taxa and metabolites to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction, the microbiota-gut-brain axis extends AD research beyond the central nervous system.

“By linking specific microbial taxa and metabolites to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction, it extends AD research beyond the central nervous system.”

The vagus nerve mediates gut-brain communication, transmitting microbial and immune signals to central circuits.

“On the other hand, the vagus nerve further mediates gut–brain communication, transmitting microbial and immune signals to central circuits.”

Broad upregulation of autophagy can lead to unintended consequences, including excessive degradation or altered immune responses.

“While autophagy enhancers (e.g., mTOR inhibitors, such as rapamycin, AMP-activated protein kinase [AMPK] activators, or transcription factor EB [TFEB] activators) have shown neuroprotective effects in preclinical models, broad upregulation can lead to unintended consequences, including excessive degradation or altered immune responses [144].”

• cites [144] Tang Y, Liu Y, Zhou H, Lu H, Zhang Y, Hua J, Liao X (2023) Esketamine is neuroprotective against traumatic brain injury through its modulation of autophagy and oxidative stress via AMPK/mTOR-dependent TFEB nuclear translocation. Exp Neurol 366:114436. https://doi.org/10.1016/j.expneurol.2023.114436 sourceNot checked — no full text of the source

These mechanisms establish a self-perpetuating cycle in which dysbiosis, systemic inflammation, and central pathology reinforce each other, accelerating AD progression.

“Hence, collectively, these mechanisms establish a self-perpetuating cycle in which dysbiosis, systemic inflammation, and central pathology reinforce each other, accelerating AD progression (Fig. 8).”

Autophagy enhancers such as mTOR inhibitors, AMPK activators, and TFEB activators have shown neuroprotective effects in preclinical models.

“While autophagy enhancers (e.g., mTOR inhibitors, such as rapamycin, AMP-activated protein kinase [AMPK] activators, or transcription factor EB [TFEB] activators) have shown neuroprotective effects in preclinical models, broad upregulation can lead to unintended consequences, including excessive degradation or altered immune responses [144].”

• cites [144] Tang Y, Liu Y, Zhou H, Lu H, Zhang Y, Hua J, Liao X (2023) Esketamine is neuroprotective against traumatic brain injury through its modulation of autophagy and oxidative stress via AMPK/mTOR-dependent TFEB nuclear translocation. Exp Neurol 366:114436. https://doi.org/10.1016/j.expneurol.2023.114436 sourceNot checked — no full text of the source

The genetic architecture of Alzheimer's disease validates and interconnects the major mechanistic hypotheses within a common etiological framework.

“Thus, the genetic architecture of AD serves to validate and interconnect these mechanistic hypotheses within a common etiological framework.”

Many Alzheimer's disease risk genes are highly expressed in microglia and immune-related tissues.

“Importantly, many of these risk genes are highly expressed in microglia and immune-related tissues, reinforcing the concept that AD pathogenesis cannot be reduced to a neuron-centric disease.”

Many Alzheimer's disease risk genes converge on amyloid processing, immune regulation, lipid and metabolic dysfunction, and autophagy-lysosomal failure.

“Many risk genes converge on previously discussed pathways, such as amyloid processing (APP, PSEN1/2), immune regulation (TREM2, CD33), lipid and metabolic dysfunction (APOE, SLC10A2), and autophagy–lysosomal failure (BIN1, CD2AP).”

Aβ plaques and tau tangles can be reframed not simply as toxic byproducts but as maladaptive defense mechanisms.

“This perspective reframes hallmark AD pathologies, i.e., Aβ plaques and tau tangles, not simply as toxic byproducts, but as maladaptive defense mechanisms.”

Probiotics containing Lactobacillus and Bifidobacterium strains, prebiotic dietary fibers, and FMT have demonstrated promise in preclinical AD models, improving cognition and reducing pathology.

“Probiotics containing Lactobacillus and Bifidobacterium strains, prebiotic dietary fibers, and fecal microbiota transplantation (FMT) have demonstrated promise in preclinical AD models, improving cognition and reducing pathology [130].”

• cites [130] Kesika P, Suganthy N, Sivamaruthi BS, Chaiyasut C (2021) Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer’s disease. Life Sci 264:118627. https://doi.org/10.1016/j.lfs.2020.118627 sourceNot checked — no full text of the source

Metabolic and mitochondrial dysfunction in Alzheimer's disease can be tracked through markers of impaired energy flux, including altered lactate dynamics, ATP turnover, and mitochondrial DNA damage.

“As discussed, metabolic and mitochondrial dysfunction can be tracked through markers of impaired energy flux, including altered lactate dynamics, ATP turnover, and mitochondrial DNA damage, while microbiota-derived metabolites, particularly SCFAs, LPS, and bile acid derivatives, are increasingly recognized as modulators of brain physiology that may serve as peripheral indicators of risk.”

Emerging evidence highlights the therapeutic potential of herbal and natural compounds, which act through pleiotropic mechanisms that align well with the multi-hit model of Alzheimer's disease.

“Emerging evidence also highlights the therapeutic potential of herbal and natural compounds, which act through pleiotropic mechanisms that align well with the multi-hit model.”

The interdependence of Alzheimer's disease pathological hubs makes it increasingly difficult to assign primacy to any single hypothesis.

“This interdependence makes it increasingly difficult to assign primacy to any single hypothesis; rather, these hubs function as interlocking gears in a self-propelling machine of neurodegeneration.”

A systems-level view suggests that hub-focused interventions, such as targeting mitochondrial resilience or modulating microglial phenotypes, may offer broader leverage than interventions aimed at single downstream features.

“First, it suggests that “hub-focused” interventions (e.g., targeting mitochondrial resilience, modulating microglial phenotypes) may offer broader leverage than interventions aimed at single downstream features.”

Genetic risk variants such as APOE4, TREM2, and BIN1 bias microglial reactivity, lipid metabolism, and endosomal trafficking, effectively priming the brain toward vulnerability.

“(i) Genetic risk variants (e.g., APOE4, TREM2, BIN1) that bias microglial reactivity, lipid metabolism, and endosomal trafficking, effectively priming the brain toward vulnerability;”

Alzheimer's disease can be reframed as a disorder of network collapse, where distinct molecular insults converge on a finite set of vulnerable nodes.

“This threshold-based model reframes AD as a disorder of network collapse, where distinct molecular insults converge on a finite set of vulnerable nodes.”

The core pathological hubs of Alzheimer's disease include amyloid, tau, mitochondrial dysfunction, and neuroinflammation.

“A critical synthesis of current evidence suggests that the “core pathological hubs” of AD include amyloid, tau, mitochondrial dysfunction, and neuroinflammation (Fig. 7).”

Alzheimer's disease emerges from a convergence of interdependent pathogenic processes rather than a single initiating insult.

“AD emerges from a convergence of interdependent pathogenic processes rather than a single initiating insult.”

Traditional linear models focused narrowly on amyloid or tau have proven insufficient to account for the interplay of genetic susceptibility, immune activation, metabolic stress, synaptic failure, and systemic influences such as microbiota and infection.

“Traditional linear models, focused narrowly on amyloid or tau, have proven insufficient to account for the interplay of genetic susceptibility, immune activation, metabolic stress, synaptic failure, and systemic influences such as microbiota and infection.”

Microglial modulators, including TREM2 agonists, CSF1R inhibitors, and NLRP3 inflammasome inhibitors, show promise in restoring protective phenotypes rather than broadly suppressing immune activation.

“Microglial modulators, including TREM2 agonists, CSF1R inhibitors, and NLRP3 inflammasome inhibitors, show promise in restoring protective phenotypes rather than broadly suppressing immune activation.”

Alzheimer's disease is not a linear cascade but a systems-level disorder arising from the convergence of multiple dysregulated networks that normally maintain neural homeostasis.

“What is now emerging is the recognition that AD is not a linear cascade, but a systems-level disorder, arising from the convergence of multiple dysregulated networks that normally maintain neural homeostasis [168].”

• cites [168] Castrillo JI, Oliver SG (2016) Alzheimer’s as a systems-level disease involving the interplay of multiple cellular networks. Methods Mol Biol (Clifton, N.J) 1303:3–48. https://doi.org/10.1007/978-1-4939-2627-5_1 sourceNot checked — no full text of the source

Many phytochemicals influence multiple convergent pathways simultaneously, making them attractive candidates for inclusion in combination therapies or as disease-modifying nutraceuticals.

“Unlike synthetic single-target agents, many phytochemicals influence multiple convergent pathways simultaneously, making them attractive candidates for inclusion in combination therapies or as disease-modifying nutraceuticals.”